NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.

PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.

ACAD reports encouraging third-quarter results as earnings and revenues beat estimates. Nuplazid and Daybue sales record year-over-year growth.

Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year...

PCRX reports mixed third-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.

RCKT incurs narrower-than-expected third-quarter 2024 loss. The company provides updates on its pipeline candidates.

ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.

ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter.

DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.